



**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Kathleen Bodine  
Type or print name

  
Signature

April 7, 2003  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF

SALVATI ET AL.

APPLICATION NO: 10/024,878

FILED: DECEMBER 19, 2001

FOR: METHODS FOR THE PREPARATION OF FUSED HETEROCYCLIC  
SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
EPOCH CENTER 1600/2900  
APR 16 2003

*1/1 election  
w/traverse  
1/13*

*Bet  
5-6-03*

**RESPONSE TO RESTRICTION REQUIREMENT AND ELECTION**

Sir:

In a paper mailed March 17, 2003, the Examiner imposed a multi-part restriction upon claims 1 and 2 of this application. Applicants appreciate the Examiner's further assistance in the telephonic communications regarding this restriction on April 2 and 3, 2003.

***Election***

In a telephone conversation, the Examiner authorized election of a representative species and a corresponding group of compounds prepared by the claimed method. Accordingly, Applicants hereby elect, with traverse, the enantiomeric compounds 221B and 222D (page 349), which are formed by the method of claim 1, and which are encompassed by the group of compounds of formula XVI wherein A<sub>1</sub> and A<sub>2</sub> are each CR<sub>7</sub>, R<sub>7</sub> being defined as in claim 1; and Z<sub>1</sub> and Z<sub>2</sub> are each O/S.

Notwithstanding this election, it is believed that the method of claim 2, wherein substituents A<sub>1</sub>, A<sub>2</sub>, Z<sub>1</sub> and Z<sub>2</sub> of formula XVIII are similarly defined, may now properly be examined with claim 1. Accordingly, commensurate revision of the restriction to permit examination of claim 2 is respectfully requested.

No fees are believed to be due in connection with this response. If it is determined that any such fees are due, Applicants will promptly remit such fees upon receipt of an appropriate notification.

The foregoing election and traversal are believed to be fully responsive to the outstanding Office Action. If a direct personal communication might advance the prosecution of this application, the Examiner is invited to contact Applicants' undersigned representative at the telephone number below.

Respectfully submitted,



Deanna L. Baxam  
Attorney for Applicants  
Reg. No. 45,266

Bristol-Myers Squibb Company

Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-4014

Date: April 7, 2003